Combined Estrogen Receptor and Progesterone Receptor Level Can Predict Survival Outcome in Human Epidermal Growth Factor Receptor 2-positive Early Breast Cancer

Chen, Mengdi; Wu, Jiayi; Liu, Deyue; Chen, Weilin; Lin, Caijin; Andriani, Lisa; Ding, Shuning; Huang, Ou; He, Jianxing; Chen, Xiaosong; Chen, Weiguo; Li, Yafen; Shen, Kunwei; Zhu, Li

doi:10.1016/j.clbc.2021.05.012

Cited by 3 publications

(3 citation statements)

References 29 publications

(23 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chen et al evaluated the impact of ER level and its impact on prognosis in HRpositive/HER2-positive BC; they distinguished ER expression as low (1-9%), median (10-79%), and high (80-100%). In the analyses, only a high ER level was strongly correlated with a better survival outcome (hazard ratio 0.09, 95%CI 0.01-0.68, p = 0.019) and the benefit continues to remain meaningful after adjustment for tumoral dimension and nodal status [8].…”

Section: Biology and Prognosis Of Hormone Receptor-positive/her2-posi...mentioning

confidence: 92%

Hormone Receptor-Positive/HER2-Positive Breast Cancer: Hormone Therapy and Anti-HER2 Treatment: An Update on Treatment Strategies

Tommasi,

Airò,

Pratticò

et al. 2024

JCM

View full text Add to dashboard Cite

Hormone receptor (HR)-positive/HER2-positive breast cancer represents a distinct subtype expressing estrogen and progesterone receptors with an overexpression of HER2. Approximately 14% of female breast cancer cases are HER2-positive, with the majority being HR-positive. These tumors show a cross-talk between the hormonal and HER2 pathways; the interaction has implications for the treatment options for the disease. In this review, we analyze the biology of HR-positive/HER2-positive breast cancer and summarize the evidence concerning the standard of care options both in neoadjuvant/adjuvant settings and in advanced disease. Additionally, we focus on new trials and drugs for HR-positive/HER2-positive breast cancer and the new entity: HER2-low breast cancer.

show abstract

Section: Biology and Prognosis Of Hormone Receptor-positive/her2-posi...mentioning

confidence: 92%

Hormone Receptor-Positive/HER2-Positive Breast Cancer: Hormone Therapy and Anti-HER2 Treatment: An Update on Treatment Strategies

Tommasi,

Airò,

Pratticò

et al. 2024

JCM

View full text Add to dashboard Cite

show abstract

“…[ 1 ] Breast cancer is classified into different subgroups depending on whether it expresses estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth factor receptor 2 (HER2). [ 2 ] Radiotherapy is one of the most important options for the cure and control of breast cancer after surgery; [ 3 ] more than 83% of breast cancer patients benefit from radiotherapy, either curative or palliative. [ 4 ] Radiation has significantly reduced the risk of local recurrence and also improved overall survival.…”

Section: Introductionmentioning

confidence: 99%

The Detection of DNA Damage Response in MCF7 and MDA-MB-231 Breast Cancer Cell Lines after X-ray Exposure

et al. 2023

View full text Add to dashboard Cite

Radiotherapy is one of the main options to cure and control breast cancer. The aim of this study was to investigate the sensitivity of two human breast cancer cell lines, MCF7 and MDA-MD-231, to radiation exposure at timepoints 4 h and 24 h after radiation. MCF7 and MDA-MD-231 were irradiated with different radiation doses using a Gilardoni CHF 320 G X-ray generator (Mandello del Lario, Italy) at 250 kVp, 15 mA [with half-value layer (HVL) = 1.6 mm copper]. The ApoTox-Glo triplex assay combines three assays used to assess viability, cytotoxicity, and apoptosis. The expression of γH2AX and BAX was analyzed by Western blotting. Viability and cytotoxicity did not change 4 h and 24 h after irradiation in either cell line, but we found a significant increase in the expression of cleaved caspase-3/7 at 24 h after irradiation with 8.5 Gy in MDA-MB231. The expression of γH2AX and BAX was low in MCF7, whereas the expression of γH2AX and BAX increased with radiation dose in a dose-dependent manner in MDA-MB231. The results show that the MCF7 cell line is more radioresistant than the MDA-MB 231 cell line at 4 h and 24 h after X-ray irradiation. In contrast, MDA-MB-231 cells were radiosensitive at a high radiation dose of 8.5 Gy at 24 h after irradiation. γH2AX and BAX indicated the radiosensitivity in both cell lines. These results open the possibility of using these cancer cell lines as models for testing new therapeutic strategies to improve radiation therapy.

show abstract

“…Among 919 early HER2(+) BC patients, there are 442 hormone receptor(+)/ HER2(+) and 477 hormone receptor(−)/HER2(+) cases [15]. There is a potential correlation between ER/PR levels and disease-free survival in hormone receptor(+)/HER2(+) BCs (p = 0.074).…”

mentioning

confidence: 99%

Immunohistochemical Study of Female Breast Cancer in Varna, Bulgaria

Yaneva,

Maslarski

2024

C. R. Acad. Bulg. Sci.

View full text Add to dashboard Cite

An immunohistochemical study of 128 female breast cancer patients in Varna is performed. The expression of estrogen and progesterone receptors, human epidermal growth factor receptor 2 (HER2) and proliferation marker protein Ki-67 in terms of histological and molecular types and differentiation grade is assessed. Ductal carcinoma and luminal B HER2(+) prevail. The discrepancies between immunohistochemical positivity and negativity of single biomarkers are outlined.

show abstract

Combined Estrogen Receptor and Progesterone Receptor Level Can Predict Survival Outcome in Human Epidermal Growth Factor Receptor 2-positive Early Breast Cancer

Cited by 3 publications

References 29 publications

Hormone Receptor-Positive/HER2-Positive Breast Cancer: Hormone Therapy and Anti-HER2 Treatment: An Update on Treatment Strategies

Hormone Receptor-Positive/HER2-Positive Breast Cancer: Hormone Therapy and Anti-HER2 Treatment: An Update on Treatment Strategies

The Detection of DNA Damage Response in MCF7 and MDA-MB-231 Breast Cancer Cell Lines after X-ray Exposure

Immunohistochemical Study of Female Breast Cancer in Varna, Bulgaria

Contact Info

Product

Resources

About